CEVI CellaVision AB (publ)

20.08USD204.00 SEK · STO+0.25%Mkt Cap: 478.93M USDP/E: 35.42

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hemat…

Institutional holders10 on file

Key Statistics

Company
Market Cap478.93M USD
Enterprise Value462.32M USD
Revenue (TTM)75.10M USD
Gross Profit51.17M USD
Net Income (TTM)15.07M USD
Revenue/Share3.15 USD
Last Price20.08 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees252
CountrySE
SectorHealthcare
IndustryMedical Devices
ISINSE0000683484
Valuation
P/E (Trailing)35.42
P/E (Forward)24.82
PEG—
EV/EBITDA23.66
EV/Revenue6.16
P/S6.38
P/B5.21
EPS (TTM)0.57 USD
EPS (Forward)0.81 USD
52W Range
11.5897% of range20.37
52W High20.37 USD
52W Low11.58 USD
Profitability
Gross Margin68.50%
Oper. Margin22.97%
EBITDA Margin26.02%
Profit Margin20.17%
ROE17.25%
ROA13.98%
ROIC21.96%
ROCE20.54%
Growth
Revenue Growth13.60%
Earnings Growth28.20%
Cash Flow & Leverage
Operating CF19.74M USD
CapEx (TTM)8.49M USD
FCF Margin13.51%
FCF Yield2.12%
Net Debt-16.61M USD
Net Debt/EBITDA-0.85
Net Debt/FCF-1.64
Balance Sheet
Debt/Equity0.03
Current Ratio3.48
Quick Ratio2.62
Book Value/Sh3.85 USD
Cash/Share0.90 USD
Dividends
Fwd Div Rate0.27 USD
Trail. Div Rate0.27 USD
Div. Yield1.35%
5Y Avg Yield0.81%
Payout Ratio47.50%
Ex-Div DateApr 29, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)19.52 USD
Upside (mean)-2.8%
Target Range17.23 USD – 21.65 USD
17.23-2.8% to mean21.65
# Analysts3
Ownership
Shares Out.23.85M
Float19.50M
Insiders18.94%
Institutions71.11%
Technical
SMA 5017.39 (+15.4%)
SMA 20014.93 (+34.5%)
Beta0.87
S&P 52W Chg12.00%
Avg Vol (30d)51.40K
Avg Vol (10d)45.09K
Technical Indicators
RSI (14)74.5
MACD8.6279
MACD Signal8.6039
MACD Hist.+0.0240
BB Upper21.47 USD
BB Middle19.06 USD
BB Lower16.65 USD
BB Width25.28%
ATR (14)0.5288 USD
Vol Ratio (20d)0.38x

About CellaVision (STO: CEVI)

›

CellaVision (STO: CEVI) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 252 employees.

The shares were at 204.00 SEK on 19 November 2026, up 29.8% over 52 weeks. Its 52-week range is 117.60 SEK to 207.00 SEK: the price is 1.4% below the high and 73.5% above the low.

At a market capitalisation of 4.87B SEK, it trades at 35.4 times trailing earnings and 24.8 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.6, a premium of 38% for CEVI. It pays a dividend yielding 1.35% (it pays out 48% of its earnings), against a median of 2.36% among the dividend payers in that peer group.

CellaVision reports return on equity of 17.2%, an operating margin of 23.0% and revenue up 13.6% year over year.

It holds more cash than debt, a net cash position of 168.72M SEK. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 3 analysts cover the stock; their mean price target of 198.33 SEK is 2.8% below the current price. The next earnings report is expected on 3 February 2027.